AddLife AB/Skr ALIF B
1D1W1MYTD1Y5YMAX
Capital at risk
About AddLife AB
AddLife AB is a company active in the life sciences sector, providing products, services, and solutions primarily to healthcare and research facilities. Its operations are divided into two major segments: Labtech, which offers laboratory equipment, diagnostics, and consumables, and Medtech, which supplies medical devices and healthcare solutions. Founded in Sweden in 2015, AddLife operates across Europe with its headquarters in Stockholm. The company's strategic focus lies in leveraging its extensive network and expertise to cater to the specialized needs of its customers, supporting advances in life sciences and medical technology.
- Ticker
- Skr ALIF B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 2,360
- Headquarters
- Stockholm, Sweden
- Website
- www.add.life
AddLife AB Metrics
BasicAdvanced
kr 19B
32.74
kr 4.89
1.57
kr 1.50
0.94%
Price and volume
Market cap
kr 19B
Beta
1.57
52-week high
kr 208.40
52-week low
kr 130.20
Average daily volume
156K
Dividend rate
kr 1.50
Financial strength
Current ratio
1.008
Quick ratio
0.565
Long term debt to equity
0.515
Total debt to equity
0.881
Dividend payout ratio (TTM)
30.43%
Interest coverage (TTM)
4.36%
Profitability
EBITDA (TTM)
1,443
Gross margin (TTM)
38.43%
Net profit margin (TTM)
5.68%
Operating margin (TTM)
8.24%
Effective tax rate (TTM)
27.36%
Revenue per employee (TTM)
kr 4,460,000
Management effectiveness
Return on assets (TTM)
4.17%
Return on equity (TTM)
10.94%
Valuation
Price to earnings (TTM)
32.741
Price to revenue (TTM)
1.853
Price to book
3.42
Price to tangible book (TTM)
-8.97
Price to free cash flow (TTM)
19.356
Free cash flow yield (TTM)
5.17%
Free cash flow per share (TTM)
8.272
Dividend yield (TTM)
0.94%
Forward dividend yield
0.94%
Growth
Revenue change (TTM)
0.82%
Earnings per share change (TTM)
77.17%
3-year revenue growth (CAGR)
4.42%
3-year earnings per share growth (CAGR)
15.50%
3-year dividend per share growth (CAGR)
7.72%
Bulls say / Bears say
AddLife beat Q2 2026 net sales estimates with a 6% y/y increase to SEK 2 721 million and delivered 11% y/y EBITA growth to SEK 342 million, lifting the EBITA margin to 12.6% and marking its strongest quarterly margin in over two years (Stockopedia)
Recent H1 acquisitions, including BioSpectrum Ltd and CoaChrom Diagnostica GmbH, are expected to contribute approximately SEK 185 million in annual net sales, reinforcing AddLife’s acquisition‐led growth strategy (Stockopedia)
Underlying organic net sales growth of 4% in Q2 2026, driven by strong demand in research and Medtech segments, highlights continued healthy end‐market momentum (AddLife)
AddLife’s Q1 2026 net sales of SEK 2.65 billion missed the SEK 2.74 billion consensus forecast, as divestitures and currency headwinds weighed on overall revenue growth (Stockopedia)
SEB downgraded AddLife to a Hold rating with a reduced price target of SEK 180, noting that the stock’s recent rally has largely eliminated its valuation discount to sector peers (MarketScreener)
Foreign‐exchange volatility reduced both Q1 2026 sales and EBITA by approximately 4%, underscoring AddLife’s material FX exposure in its European markets (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing AddLife AB
AllEURGBPUSD
Fund name | Fund size | Skr ALIF B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.11% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.11% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.